Investment
Features
FeesSafety
Academy
More
Pluang+

Weyerhaeuser and Rayonier offer strong value with attractive dividends after share price drops

Market News
04 Oct 2026
Seeking Alpha
View Source
Bullish
Weyerhaeuser and Rayonier offer strong value with attractive dividends after share price drops

Weyerhaeuser (WY) and Rayonier (RYN) present compelling investment opportunities due to recent share price weakness, offering attractive dividend yields and undervalued metrics. WY benefits from integrated scale, manufacturing leverage, and valuable land assets, while RYN offers exposure to Southern U.S. land and development potential following a merger. Analysts see potential upside with WY favored for higher returns and RYN for better current yield and growth options. Investors should consider conservative assumptions for asset and earnings stability when evaluating these stocks.

The story on two beaten-down timber REITs offers context for readers following real estate stocks. For readers following the real estate sector, here is Pluang's market snapshot as of Oct 04, 2026 15:21 WIB: Among 26 priced US real estate stocks, 14 rose and 12 fell. EPR Properties gained 1.73% to USD 56.45 with a typical hold time of 45 days, Opendoor Technologies rose 1.67% to USD 2.44 with a 33-day hold, while ARMOUR Residential REIT declined 1.59% to USD 13.59 despite 100% buy order activity and a notably longer hold time of 138 days.

More News

SpaceX stock has only once closed above $200; forecast says it will happen again by 2028.

SpaceX stock has only once closed above $200; forecast says it will happen again by 2028.

SpaceX's stock price has reached a closing value above $200 only one time so far. Analysts predict that the stock will close above this $200 mark again before the year 2028. This forecast suggests potential growth and renewed investor interest in Spa...

Analyst Insights
Bullish
3 hours ago
Pyxis Oncology advances MICVO cancer drug with promising early data and strong financing for Phase 3 trials

Pyxis Oncology advances MICVO cancer drug with promising early data and strong financing for Phase 3 trials

Pyxis Oncology is developing MICVO, an antibody-drug conjugate aimed at targeting tissues around tumors to kill cancer cells. Early clinical data for MICVO has been promising, but the company still needs to determine a safe and effective dosage. Rece...

Market News
Bullish
4 hours ago
Dogecoin stalls near $0.093 after failing to break key $0.098 resistance level

Dogecoin stalls near $0.093 after failing to break key $0.098 resistance level

Dogecoin (DOGE) reached a high of about $0.0976 on October 2 but failed to break through the crucial resistance level around $0.098-$0.10, closing near $0.093. Despite strong buying from large holders and $2.9 million inflows into U.S. Dogecoin inves...

Market News
Neutral
4 hours ago
Nike stock upgraded to Buy with 52% upside despite recent weak earnings and challenges.

Nike stock upgraded to Buy with 52% upside despite recent weak earnings and challenges.

Freedom Broker upgraded Nike shares from Sell to Buy, citing confidence in the company's long-term turnaround strategy despite weak near-term results. Nike's stock has fallen about 53% over the past year, but the new $51 price target implies a 52% up...

Analyst Insights
Bullish
4 hours ago
Ethereum struggles to break $2,800 amid weak ETF demand but eyes $3,000 with upcoming Glamsterdam upgrade.

Ethereum struggles to break $2,800 amid weak ETF demand but eyes $3,000 with upcoming Glamsterdam upgrade.

Ethereum (ETH) closed near $2,687 on Oct. 4, failing to sustain a breakout above the key $2,800 resistance level that could lead to a push toward $3,000. Institutional demand has weakened, with U.S. spot Ethereum ETFs seeing net outflows over three c...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App